Pharmacological Benefits of Multifaceted Mode Of Action For A Novel Combination Of Long-Acting GLP-2 Analog (HM15912) And GLP-1ra (Efpeglenatide) In Animal Model Of Inflammatory Bowel Disease. (April 2023)